Limited distal duodenal resection: Surgical approach and outcomes. A case series

Ankush Golhar*, Vivek Mangla, Siddharth Mehrotra, Shailendra Lalwani, Naimish Mehta, Samiran Nundy

Department of Surgical Gastroenterology and Liver Transplantation (Unit 1), Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi, 110060, India

ARTICLE INFO

Keywords:
Limited distal duodenectomy
Gastrointestinal stromal tumours
Duodenal adenocarcinoma
Segmental duodenectomy
Duodenal neuroendocrine tumours

ABSTRACT

Introduction: Tumours involving the duodenum are usually treated with pancreaticoduodenectomy, which may be associated with considerable morbidity. Limited distal duodenal resection, a relatively smaller procedure, can be done in some of these patients. We describe our experience with this operation for such lesions.

Methods: We retrospectively analyzed, from prospectively collected data 10 consecutive patients who underwent limited duodenal and proximal jejunal resection between March 2011 and Nov 2015.

Results: There were 8 males and 2 females who had a median age of 47 years. Their common presentations were abdominal pain (50%) and upper gastrointestinal bleeding (40%). Five had malignancy (adenocarcinoma: 2, neuroendocrine tumours: 2, non Hodgkin’s lymphoma 1). Three had gastrointestinal stromal tumours (GISTs) and 2 had other benign tumours (lipoma 1, ectopic pancreas 1). The 30-day post-operative morbidity rate was 60% (n = 6) with mostly minor complications (Clavien grade 1 or 2). Median post-operative stay was 9 (range, 6–13) days. All ten patients were alive without recurrence after a median follow up of 26.5 months.

Conclusion: Limited distal duodenal resection is a feasible surgical alternative to a pancreaticoduodenectomy in carefully selected patients with benign and some malignant tumours of the third and fourth part of the duodenum.

1. Introduction

Resection of the duodenum with pancreaticoduodenectomy and bilioenteric, pancreaticoenteric and gastroenteric reconstruction still has a considerable morbidity (30–50%) [1]. Limited duodenal resection is an alternative to pancreaticoduodenectomy for benign and some malignant tumours of the duodenum with the hope of decreasing morbidity and achieving equivalent oncological outcomes [2–5,7–15]. Duodenal adenocarcinoma accounts for 45% of small bowel adenocarcinomas and 0.4% of all gastrointestinal malignancies [6]. The role of limited duodenal resection for malignant tumours of third (D3) and fourth (D4) part of duodenum without pancreatic and ampullary involvement has been evaluated in some recent studies [9,10,13,14]. We studied our experience with limited resection of the duodenum for selected malignant and benign distal duodenal and proximal jejunal tumours.

2. Methods

We retrospectively analyzed prospectively collected data of all patients who underwent limited resection of the duodenum from March 2011 to March 2016 in our unit. Ten patients underwent limited resection of the duodenum for tumours of its third and fourth part or the proximal jejunum. A limited resection of the duodenum i.e. either local wedge excision or segmental duodenectomy with duodenojejunal anastomosis with preservation of the pancreas was performed by a surgeon with at least five years experience in gastrointestinal surgery in a tertiary care academic institute. The patients’ demographic data, clinical history, peri-operative details, post-operative outcomes (morbidity and 30 day mortality) and histopathological data were evaluated. Patients who underwent endoscopic excision, emergency surgical procedures, trans-duodenal ampullectomy/polypectomy or pancreatic-duodenectomy were excluded from the study. We have reported this work in line with the standard “preferred reporting of case series in surgery” (PROCESS) criteria [16].

* This work has been reported in line with the PROCESS criteria.

Corresponding author. P1/602, Empire Estate, Chinchwad, Pune, Maharashtra, 411019, India.
E-mail address: ankush9golhar@gmail.com (A. Golhar).

https://doi.org/10.1016/j.amsu.2018.04.005

Received 20 October 2017; Received in revised form 3 April 2018; Accepted 5 April 2018

2049-0801/ © 2018 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
2.1. Surgical technique

The surgical technique consisted of Kocherization of the duodenum along with the Cattell and Braash maneuver followed by mobilization of the ligament of Treitz [9]. The whole of the small bowel, ascending colon and proximal transverse colon were retracted cranially to expose the duodenojejunal junction. This junction was then mobilized dividing the ligament of Treitz. The jejunum was passed to the right side below the superior mesenteric vessels. Depending upon the location of the tumour, dissection of the third part of the duodenum from the uncinate process of the pancreas was carried out. Small and benign tumours were managed by wedge resection of the duodenum. T-tube stents were inserted depending upon the proximity of the resection margin to the ampulla. We did intra-operative endoscopy in two patients, one with a D3 adenocarcinoma to identify the ampulla and the other with a duodenal lipoma to rule out other lesions. Reconstruction was done by a gastrojejunoanastomosis (with closure of the duodenal defect) in two patients, and side-to-side duodenojejunal anastomosis (Figs. 1 and 2) in the rest. A feeding jejunostomy (FJ) was added depending upon the pre-operative and intra-operative assessment.

3. Results

3.1. Demographics and operative details

The characteristics of the 10 patients are shown in Tables 1 and 2. There were 8 males and 2 females, who had a median age of 47 years (range, 35–70). The most common clinical presentations were abdominal pain (n = 5, 50%), and upper gastrointestinal bleeding (melena n = 4, 40%), followed by vomiting (n-3, 30%). The diagnosis was a gastrointestinal stromal tumour (GIST) in 3 (30%); primary duodenal adenocarcinoma in 2 (20%); neuroendocrine tumour in 2 and duodenal and proximal jejunal non Hodgkin’s lymphoma (NHL), lipoma of the duodenum with duodenal diverticulum and ectopic pancreatic tissue in the wall of D3 part of the duodenum in one each. Eight patients underwent segmental duodenal resection and the rest had excision of a small wedge of the duodenal wall. The patient with a NHL required en bloc resection of the proximal jejunum, fourth part of duodenum and splenic flexure of the colon for a large tumour involving all these structures.

The median duration of surgery was 245 (range, 90–300) minutes (Table 3). The median intra-operative blood loss was 240 (range, 100–500) ml. Four patients who had presented with upper gastrointestinal bleeding required peri-operative blood transfusion of anaemia.

3.2. Morbidity

Postoperative morbidity was graded as per Clavien Dindo classification (grade I minor deviation form normal postoperative course, grade II complications requiring therapeutic drugs outside of those allowed in grade I, grade III requiring surgical, endoscopic or radiological intervention, grade IV life threatening complications) [17]. Complications occurred in 6 (60%) patients, grade 1 or 2 in 5 (50%) patients and Clavien Grade IV in 1 (10%) patient who developed lower respiratory infection with respiratory distress requiring ICU stay. Delayed gastric emptying (DGE) was seen in six (60%) patients. Grade A and B DGE was seen in two (33.3%) and four (66.6%) patients respectively. There were no other complications. An oral gastrografin follow through study was done between post-operative day 4 and 7 in all patients except the one with respiratory distress who underwent contrast enhanced computed tomography (CECT) to confirm the anastomotic integrity. One patient had mechanical obstruction due to narrowing at the FJ site. DGE improved with conservative management in all patients with a high nasogastric aspirate. There was no anastomotic leak. The median post-operative hospital stay was 9 days (range, 6–13 days).

3.3. Follow up and outcomes

All patients had R0 resections. All three patients with GISTs had low risk features for recurrence and did not receive any adjuvant treatment. Both patients with adenocarcinoma received adjuvant chemotherapy. They were asymptomatic and free of recurrence at a follow up duration.
of 47 months and 6 months respectively. All ten patients are alive at a median follow up period of 26.5 (range, 3–58) months.

Two patients had nonfunctioning duodenal neuroendocrine tumours. One of the patients with a neuroendocrine tumours had metastasis in a single lymph node while another patient had metastasis in a single liver nodule as well in one out of twelve lymph nodes resected and both the patients were asymptomatic at a follow up of 29 and 3 months respectively. The patient with a NHL had presented with upper gastrointestinal bleeding with a large mass in the upper abdomen. Pre-operative biopsy was suggestive of a granulomatous inflammation. Postoperative histopathological analysis however showed a diffuse large B cell type NHL with CD 20 and leucocyte common antigen (LCA) positive tumour cells. The patient received chemotherapy post-operatively and was recurrence free at 45 months of follow up. The two patients with an ectopic pancreas in the duodenum and a duodenal lipoma were asymptomatic at follow up of 24 and 52 months respectively.

4. Discussion

The duodenum has a complex anatomy with its retroperitoneal location adjacent to major vascular structures and therefore, duodenal resection is a surgically challenging procedure. Limited resection for duodenal tumours can be divided into a pancreatic sparing total or subtotal duodenectomy, pancreas sparing proximal duodenectomy and a pancreas sparing distal duodenectomy [7]. A pancreas sparing subtotal duodenectomy involves resection of the whole duodenum except the gastric pylorus and the duodenal bulb. A pancreas sparing proximal duodenectomy entails resection of the first and proximal second portion of the duodenum while in distal duodenectomy the third, fourth and distal second portion of the duodenum are resected [7].

Limited resection of the distal duodenum may entail either a local wedge resection or segmental resection. Our protocol for evaluation and management of patients with distal duodenal pathology is briefly presented in Fig. 3. If a duodenal pathology is suspected on clinical examination, we perform detailed upper gastrointestinal endoscopic examination including side-viewing endoscopy and endoscopic ultrasound as indicated along with cross sectional imaging with multi-detector CECT (Fig. 4). In patients with obvious involvement of the major duodenal papilla, we perform pancreatocoduodenectomy after thorough assessment for ruling out metastatic disease. If the major duodenal papilla is free or if there is ambiguity after imaging and endoscopic evaluation, we do thorough surgical assessment including intraoperative endoscopic evaluation. For small benign tumours of the third and fourth part of duodenum with adequate residual lumen after resection, we perform wedge resection of the lesions with duodenal re-repair. The defect after a wedge resection may be closed primarily, by applying jejunal patch or with a Roux en-Y duodenal intubation [8,14]. It is our practice to perform the gastrojejunostomy in such patients to minimize the effects of small duodenal leak and stenosis. For benign tumours of second part of the duodenum, we perform wedge resection only if adequate margin of resection without threatening the major papilla can be achieved. We do segmental duodenal resection for selected malignant distal duodenal and duodenjejunal tumours as well as benign tumours in which wedge resection will likely cause duodenal narrowing. An extended Kocher maneuver with full mobilization of the duodenum and proximal jejunum is important for creation of a tension free duodenjejunal anastomosis. We used the Cattell and Braash maneuver for distal duodenal exposure in 8 out of ten patients in our series and we feel it is extremely useful for this purpose as has also been described previously [9,10].

Although a duodenjejunal anastomosis may be performed in an end-to-end, side-to-side or an end-to-end fashion [10,11], we prefer a side-to-side duodenojugal anastomosis. Dorcaratto et al. [13] reported more complications and longer postoperative stay in patients with end to side compared to end-to-end anastomoses. There are limited studies to address this issue, and hence definitive conclusions regarding choice of anastomotic technique cannot be drawn [10–13].

The median operative time and blood loss (245 min and 240 ml respectively) in our study were lower compared to most of the previously reported series (range of 130–300 min and 160–1100 ml respectively) [9,10,12,13]. DGE (60%) was the most common post-operative complication. Although anastomotic leak, bleeding and post-operative pancreatitis, have been reported in patients undergoing limited duodenal resection, we did not encounter these complications [13,14].

Surgical resection is the only curative treatment for GISTs and a limited duodenal resection is a good option for duodenal GISTs [15]. These tumours are usually well encapsulated, lymphatic spread is rare and a small margin of clearance is sufficient [18,19]. Routine lymphadenectomy is not recommended for GISTs unless the lymph nodes are grossly involved [11]. Even though the literature on limited duodenal resection describes only small numbers of patients, equivalent disease free and overall survival have been reported with limited duodenal resection as compared to pancreatocoduodenectomy [4,5,11,13]. Our results show that the limited resection of duodenal

### Table 1

| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | Case 10 |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Age (Years) | 52 | 70 | 40 | 43 | 52 | 37 | 35 | 44 | 50 | 58 |
| Sex | M | F | M | M | M | M | F | M | |
| Symptoms | Upper GI bleed | Upper GI bleed | Abdominal pain | Upper GI bleed | Abdominal pain, vomiting and fever | Upper GI bleed | Abdominal pain, recurrent fever, vomiting, fever | Upper GI bleed | Abdominal pain | Vomiting | Abdominal pain |
| Comorbidities | No comorbidities | HTN, CLD | None | HTN, CLD | None | II | Proximal jejunal tumour | None | None | None | None |
| ASA score | III | II | I | III | II | I | D3 | None | None | None | None |
| Preoperative Diagnosis | Tumour D3 with duodenal diverticulum | Tumour D4 | Tumour D3 | Tumour D3 | Tumour D4 | Tumour D4 | Tumour D4 | Tumour D4 | Tumour D4 | Tumour D3 with lymph nodal mass |
| Tumour Size (cm) | 3.5 × 3 | 11 × 1.5 | 3 × 2 | 4 × 2 | 4 × 2 | 4 × 2 | 8 × 6 | 11 × 10 | 3 × 2 | 2 × 2 |
| No. of segments resected | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 2 |

**Acronyms:** CLD: Chronic liver disease, D2: second portion of the duodenum, D3: third portion of duodenum, D4: fourth portion of duodenum, DJ: Duodenojejunal flexure, HTN: systemic hypertension, HIV: Human immunodeficiency virus, M: Male, F: Female.
GISTs is a feasible option and good long-term disease free survival can be achieved.

Adenocarcinoma involving the fourth part of duodenum and proximal jejunum can also be treated with a limited duodenal resection. In a study by Onkendi et al. [14] even though the average lymph nodes sampled in segmental duodenectomy group were 8 compared to 12 in the pancreaticoduodenectomy group, there was no survival difference between the two groups. Also, a couple of other studies have reported similar survival outcomes and negligible morbidity with limited duodenal resection in patients with duodenal adenocarcinoma involving the distal part of the duodenum [9,20]. These reports and our study show that the limited distal duodenal resection can be a feasible option for malignant distal duodenal tumours with comparable survival outcomes to pancreaticoduodenectomy [9,14,20].

Duodenal neuroendocrine tumours account for 2–3% of all gastrointestinal neuroendocrine tumours [21]. As indicated in few previous reports, ours study also found that these tumours can be managed by limited duodenal resection with satisfactory long-term survival rates even in the presence of lymph node metastases [22,23].

GISTs is a feasible option and good long-term disease free survival can be achieved.

Adenocarcinoma involving the fourth part of duodenum and proximal jejunum can also be treated with a limited duodenal resection. In a study by Onkendi et al. [14] even though the average lymph nodes sampled in segmental duodenectomy group were 8 compared to 12 in the pancreaticoduodenectomy group, there was no survival difference between the two groups. Also, a couple of other studies have reported similar survival outcomes and negligible morbidity with limited duodenal resection in patients with duodenal adenocarcinoma involving the distal part of the duodenum [9,20]. These reports and our study show that the limited distal duodenal resection can be a feasible option for malignant distal duodenal tumours with comparable survival outcomes to pancreaticoduodenectomy [9,14,20].

Duodenal neuroendocrine tumours account for 2–3% of all gastrointestinal neuroendocrine tumours [21]. As indicated in few previous reports, ours study also found that these tumours can be managed by limited duodenal resection with satisfactory long-term survival rates even in the presence of lymph node metastases [22,23].

4.1. Limitations

The rarity of patients with disease amenable to this surgical procedure limits the size of our study. However our data, documents the feasibility and safety of performing a limited duodenal resection for benign and selected malignant tumours of the distal duodenum. A well-designed prospective study is needed to establish the oncological equivalence of this procedure to pancreaticoduodenectomy in patients with distal duodenal adenocarcinoma.

5. Conclusion

Limited duodenal resection is a feasible option for selected patients with tumours involving the distal duodenum and/or proximal jejunum with good short-and long-term outcomes.
Ethical approval

None.

Funding for your research

None.

Author contribution

1) Ankush Golhar: Study design and planning, data acquisition, clinical work, drafted the manuscript.
2) Vivek Mangla: Study design and planning, clinical work, data acquisition, manuscript revision.
3) Siddharth Mehrotra: Data acquisition, clinical work and drafted the manuscript.

Fig. 3. Algorithm for evaluation and management of distal duodenal pathology.

Fig. 4. Computed tomography images in case no. 5 showing growth in the third part of duodenum (Arrows pointing towards growth).
4) Shailendra Lalwani: Data acquisition, Clinical work and manuscript revision
5) Naimish Mehta: Data acquisition, Clinical work and manuscript revision
6) Samiran Nundy: Design of work, clinical work and manuscript revision.

Conflicts of interest

None.

Research registration number

researchregistry2661.

Trial registry number

Not applicable

Guarantor

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Dr Ankush Golhar, Dr Vivek Mangla, Dr Samiran Nundy.

Grants

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] M.L. DeOliveira, J.M. Winter, M. Schafer, et al., Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy, Ann. Surg. 244 (2006) 931–939.
[2] P. Gervaz, O. Huber, P. Morel, Surgical management of gastrointestinal stromal tumours, Br. J. Surg. 96 (2009) 567–578.
[3] J.C. Chung, H.C. Kim, S.M. Huh, Limited resections for duodenal gastrointestinal stromal tumours and their oncologic outcomes, Surg. Today 46 (2016) 110–116.
[4] B. Zhu, M. Zhang, J. Wu, et al., Pancreaticoduodenectomy versus local resection in the treatment of gastrointestinal stromal tumours of the duodenum, World Journal of Surgical Oncology 11 (2013) 1–6.
[5] J.C. Chung, C.W. Chu, G.S. Cho, et al., Management and outcome of gastrointestinal stromal tumours of the duodenum, J. Gastrointest. Surg. 14 (2010) 880–883.
[6] A. Struck, T. Howard, E.G. Chiorean, et al., Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival, J. Surg. Oncol. 100 (2009) 144–148.
[7] M. Konishi, T. Kinoshita, T. Nakagohri, et al., Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies, Hepato-Gastroenterology 54 (2007) 753–757.
[8] R.K. Goh, P.K. Chow, H.S. Ong, W.K. Wong, Gastrointestinal stromal tumour involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunojunostomy, J. Surg. Oncol. 91 (2005) 273–275.
[9] A. Tocchi, G. Mazzoni, F. Puma, et al., Adenocarcinoma of the third and fourth portions of the duodenum: results of surgical treatment, Arch. Surg. 138 (2003) 80–85.
[10] P.J. García-Molina, F. Mateo-Vallejo, J. de Dios Franco-Osorio, J.L. Esteban-Ramos, I. Rivero-Henández, Surgical approach for tumours of the third and fourth part of the duodenum. Distal pancreas-sparing duodenoectomy, Int. J. Surg. 18 (2015) 143–148.
[11] X. Liang, H. Yu, L.H. Zhu, X.F. Wang, X.J. Cai, Gastrointestinal stromal tumours of the duodenum: surgical management and survival results, World Journal of Gastroenterology 19 (2013) 6000–6010.
[12] D.R. Spalding, A.M. Isha, J.N. Thompson, R.C. Williamson, Pancreas-sparing distal duodenectomy for infrapapillary neoplasms, Ann. R. Coll. Surg. Engl. 89 (2007) 130–135.
[13] D. Dorcaratto, H.M. Henehan, B. Fiore, et al., Segmental duodenal resection: indications, surgical techniques and postoperative outcomes, J. Gastrointest. Surg. 19 (2015) 736–742.
[14] E.O. Oskendi, S.Y. Boostrom, M.G. Sarr, et al., 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas, J. Gastrointest. Surg. 16 (2012) 682–691.
[15] E.M. Connelly, E. Gaffney, J.V. Reynolds, Gastrointestinal stromal tumours, Br. J. Surg. 90 (2003) 1178–1186.
[16] R.A. Agha, A.J. Fowler, S. Rajmohan, I. Barai, D.P. Orgill, PROCESS Group. Preferred reporting of case series in surgery; the PROCESS guidelines, Int. J. Surg. 36 (2016) 319–323.
[17] D. Dindo, N. Demartines, P.A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann. Surg. 240 (2004) 205.
[18] P. Bucher, J.F. Egger, P. Gervaz, et al., An audit of surgical management of gastrointestinal stromal tumours (GIST), Eur. J. Surg. Oncol. 32 (2006) 314–318.
[19] J.S. Gold, R.P. DeMatteo, Combined surgical and molecular therapy: the gastrointestinal stromal tumour model, Ann. Surg. 244 (2006) 176–184.
[20] F.G. Bakaeen, M.M. Murr, M.G. Sarr, et al., What prognostic factors are important in duodenal adenocarcinoma? Arch. Surg. 135 (2000) 635–642.
[21] K.M. Ho, C.L. Liu, C.C. Hsu, et al., Duodenal neuroendocrine tumours: resect or enucleate? J. Gastrointest. Surg. 13 (2009) 143–151.
[22] C.S. Pitt, H.A. Pitt, M.S. Baker, et al., Small pancreatic and periampullary neuroendocrine tumours: resect or enucleate? J. Gastrointest. Surg. 13 (2009) 1492–1498.
[23] P.H. Jordan, A personal experience with pancreatic and duodenal neuroendocrine tumours, J. Am. Coll. Surg. 189 (1999) 470–482.